However, given that the acquisition of tumor resistance to systemic treatment often involves restoration of BRCA1/2 function, it is essential to ensure that patients with BRCA1/2-driven tumors receive BRCA1/2-specific drugs (e.g., platinum-based regimens) in the very beginning of therapeutic intervention. Here, BRCA1 is linked to neoplasm.